BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $666.201M Est

Benzinga Newsdesk www.benzinga.com Negative 60.6%

Neg 60.6% Neu 0% Pos 0%

BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million vs $666.201 million estimate.